Confirmation of Directorate Change

RNS Number : 3221F

Diaceutics PLC

18 March 2022

 

18 March 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Confirmation of Directorate Change

Further to the Company's announcement on 11 January 2022, Diaceutics confirms the appointment of Nick Roberts to the Board as Chief Financial Officer effective today, 18 March 2022.

Accordingly, the Company announces that Philip White has stepped down from the Board and as Chief Financial Officer.

The Company confirms that there are no additional disclosures required under the AIM Rules in relation to the appointment of Nick Roberts, further to the announcement dated 11 January 2022. 

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison, Stewart Wallace, Nick Adams
Alma PR	Tel: [phone]
Caroline Forde, Kieran Breheny, Matthew Young	[e-mail]

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

END

 

 

BOAGPUMUWUPPGCR